Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Drug Administration Schedule
Female
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Male
Maximum Tolerated Dose
Melphalan
/ administration & dosage
Multiple Myeloma
/ drug therapy
Oligopeptides
/ administration & dosage
Patient Safety
Prednisone
/ administration & dosage
Response Evaluation Criteria in Solid Tumors
Survival Rate
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2019
15 07 2019
Historique:
received:
06
11
2018
revised:
18
01
2019
accepted:
29
04
2019
pubmed:
6
5
2019
medline:
23
9
2020
entrez:
5
5
2019
Statut:
ppublish
Résumé
Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile. IFM2012-03, a phase I multicenter study of KMP weekly in elderly patients with newly diagnosed multiple myeloma (eNDMM), aimed to determine the MTD of carfilzomib. Carfilzomib was given intravenously at 36, 45, 56, and 70 mg/m Thirty eNDMMs were treated, 6 per cohort at 36, 45, and 56 mg/m The MTD dose of carfilzomib was 70 mg/m
Identifiants
pubmed: 31053600
pii: 1078-0432.CCR-18-3642
doi: 10.1158/1078-0432.CCR-18-3642
doi:
Substances chimiques
Oligopeptides
0
carfilzomib
72X6E3J5AR
Melphalan
Q41OR9510P
Prednisone
VB0R961HZT
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4224-4230Informations de copyright
©2019 American Association for Cancer Research.